1-3 of 3
Xue Lan Zuo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-term efficacy and safety of ropeginterferon alfa-2b under its hidat regimen for the treatment of polycythemia vera

Free
Shanshan Suo, Rongfeng Fu, Albert Qin, Zonghong Shao, Jie Bai, Hu Zhu, Na Xu, Suning Chen, Xue Lan Zuo, Xin Du, Minghui Duan, Li Wang, Pei Li, Xuhan Zhang, Sujiang Zhang, Daoxiang WU, Jingjing Zhang, Zhijian Xiao, Lei Zhang, Jie Jin
Journal: Blood
Blood (2025) 146 (Supplement 1): 2039.
https://doi.org/10.1182/blood-2025-2039
Published: 2025
Journal Articles

Safety and efficacy of the JAK/rock inhibitor rovadicitinib in combination with the bromodomain and extra-terminal inhibitor TQB3617 in patients with myelofibrosis: A phase ib/II study

Free
Chunkang Chang, Xuliang Shen, Hu Zhou, Min Zhang, Zongjiu Jiao, Sujun Gao, Zhenya Hong, Zhihua Zhang, Jianping Hao, Tiejun Gong, Hongmei Ma, Xue Lan Zuo, Guohua Yang, Junying Wu, Luxi Song, Duoer Wu, Dawei Ding, Shanli Lao, Ding Yu
Journal: Blood
Blood (2025) 146 (Supplement 1): 481.
https://doi.org/10.1182/blood-2025-481
Published: 2025
Journal Articles

Analysis of non-driver mutation characteristics in primary myelofibrosis

Free
yueru luo, yixuan li, Xinhai Deng, keyi chen, Sanyun Wu, Xue Lan Zuo, Fuling Zhou, li he
Journal: Blood
Blood (2025) 146 (Supplement 1): 7329.
https://doi.org/10.1182/blood-2025-7329
Published: 2025